Clinical trial
Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia
NCT00233454 · Jason Robert Gotlib, Other · Completed
Key facts
| NCT number | NCT00233454 |
|---|---|
| Title | Phase 2 Midostaurin in Aggressive Systemic Mastocytosis and Mast Cell Leukemia |
| Official title | A Single Arm, Phase 2, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 <Midostaurin> Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL) |
| Lead sponsor | Jason Robert Gotlib, Other |
| Collaborators | Novartis Industry Novartis Pharmaceuticals |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Systemic Mastocytosis, Aggressive (ASM), Leukemia, Mast Cell, Hematological Non-mast Cell Lineage Disease (AHNMD) |
| Intervention type | Drug |
| Interventions | Midostaurin |
| Enrollment | 26 |
| Start date | Mar 1, 2005 |
| Primary completion | Jun 18, 2010 |
| Completion | Apr 16, 2011 |
| First posted | Oct 5, 2005 |
| Last update posted | Sep 20, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: